Unlocking Opportunities in the Glomerulonephritis Market: Key Growth Trends and Forecast Insights
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Growth Potential of the Glomerulonephritis Market, and How Will It Perform by 2034?
In the last few years, the glomerulonephritis market has exhibited substantial growth. It’s projected to escalate from $11.06 billion in 2024 to $11.64 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.3%. This progression during the historic period was driven by factors such as the escalating incidence of kidney diseases, the widespread prevalence of infections like post-streptococcal glomerulonephritis, an uplift in research and development, a rise in kidney failure cases, and the enhanced awareness about kidney disorders.
Expectations are high for substantial growth in the glomerulonephritis market in the coming years, with projections suggesting an escalation to $14.14 billion by 2029, at a compound annual growth rate (CAGR) of 5.0%. This anticipated growth during the forecast period can be attributed to several factors, including increasing rates of diabetes, an expanding older population, escalating investments in healthcare spending, a rise in the number of dialysis patients, and a surge in autoimmune disease cases. The forecast horizon also indicates significant trends, such as the introduction of innovative treatments and therapies, advancements in diagnostic technologies, new therapeutics and therapies, collaboration initiatives between industry companies, and the use of intravenous immunoglobulin therapy.
Which Drivers Are Expected to Have the Greatest Impact on the Glomerulonephritis Market’s Growth?
The glomerulonephritis market is anticipated to expand due to the increasing rate of kidney disorders. Such disorders encompass an array of conditions, impacting the kidneys’ structure or function, and result in compromised filtration, waste elimination, and fluid regulation. A surge in kidney disorders can be attributed to factors like an aging demographic, growing instances of chronic diseases such as diabetes and hypertension, and lifestyle decisions. These disorders lead to glomerulonephritis through provoking immune system anomalies, persistent inflammation, or structural harm, leading to hindered kidney filtration and function. For example, the Australian Institute of Health and Welfare, a government institution based in Australia, reported in December 2024 that chronic kidney disease (CKD) death rates rose by 4.2% in 2021 and 6.2% in 2022. Between 2021 and 2022, CKD accounted for about 2 million hospitalizations or 18% of all hospital stays in Australia. Hence, the escalating rate of kidney disorders is anticipated to fuel the glomerulonephritis market’s growth.
Get Your Free Sample of the Global Glomerulonephritis Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp
Who Are the Major Companies Shaping the Competitive Landscape of the Glomerulonephritis Market?
Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.
What Are the Key Emerging Trends in the Glomerulonephritis Market for the Next Decade?
The glomerulonephritis market is witnessing leading businesses prioritise the creation of progressive non-immunosuppressive therapies to address medical needs that are currently unserviced and enhance patient outcomes. Non-immunosuppressive treatments, which do not compromise or reduce the strength of the immune system, are used to treat diseases without affecting immune activities. For instance, in September 2024, Travere Therapeutics Inc., a biopharmaceutical business based in the US, launched FILSPARI (sparsentan). This drug, endorsed by the Food and Drug Administration (FDA), is used for managing IgA nephropathy, a kidney-related disease. FILSPARI has proven to be the sole non-immunosuppressive treatment that noticeably slows down the worsening of kidney functioning in patients. This validation of FILSPARI denotes a significant step forward in treating IgA nephropathy, which has the highest incidence rate among primary glomerulonephritis. This therapy creates a new alternative for patients who previously had only a few options. This endorsement underscores Travere’s dedication to enhancing results for patients with kidney disease.
Get Instant Access to the Global Glomerulonephritis Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report
What Are the Core Categories and Segments in the Glomerulonephritis Market Driving Demand and Growth?
The glomerulonephritis market covered in this report is segmented –
1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis
2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis
3) By Treatment: Medication, Surgery, Dialysis, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome
2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis
Which Regions Are Making a Mark in the Glomerulonephritis Market Growth?
North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Is the Glomerulonephritis Market Categorized and Defined in the Industry?
Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys that remove waste and excess fluids from the blood. It can result from infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in urine, proteinuria, and swelling. If left untreated, it may progress to chronic kidney disease or kidney failure.
Browse Through More Similar Reports By The Business Research Company:
Suture Laparoscopic Forceps Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/suture-laparoscopic-forceps-global-market-report
Electrocautery Enhanced Delivery System Global Market Report 2025
Anemia and Other Blood Disorder Drugs Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
